Episode five with Jessica Carmen, Consultant, Pullan Consulting
Jessica compares the gene therapy industry to the poem ‘A Road Less Travelled’, in that the industry isn’t entirely untrodden but the track is rough and hard to follow. Although, that doesn’t mean we shouldn’t take it.
This episode was delivered in a context of being second to market, where the first product is not ‘best in class’ and the room for innovation and improvement is vast.
Jessica takes us through the gene therapy toolbox (viral vectors, poration technologies, gene-editing tools, exosomes) to consider what’s viable, scalable and where the big potential lies, most notably, the CRISPR-mediated delivery of a CAR by electroporation.
This innovation is having an impact. The rate of products entering the clinic is matched only by the rate of investment in the sector. A clear example of this is CRISPR, Elizabeth Charpentier and Jennifer Doudna’s paper was published in 2012 and by 2015 it was a $1bn industry.
Watch this episode of Phacilitate:TALKS to find out more about Jessica’s take on the next generation of gene therapy…
There are 12 episodes in the Phacilitate:TALKS series, which you can find here. You can also join the Phacilitate membership for more insight and analysis on the advanced therapies industry straight to your inbox.